Understanding the Impact of an HIV Intervention Package for Adolescents

Similar documents
Where are we going after effectiveness studies?

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA

Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012

HIV Prevention Strategies HIV Pre-exposure prophylaxis

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

Biomedical Prevention in HIV

Biomedical Prevention Update Thomas C. Quinn, M.D.

Overview of ARV-based prevention trials

The Open Label Trial Past and Present

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Drug development in relation to PrEP and the PROUD study

Understanding the Results of VOICE

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

PREPARING FOR PREP: FROM KEY POPULATIONS THEORY TO PRACTICE. Dr Oscar Radebe

Update on PrEP progress: WHO/UNAIDS challenges and actions

PEP and PrEP: AWAAC 2014

Using anti-hiv drugs for prevention

Antiretrovirals for HIV prevention:

Combination HIV Prevention

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

CAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina

The Open Label Trial Past and Present

Combination prevention: Public health and human rights imperatives

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

Dr Valérie Martinez-Pourcher

Update on ARV based PrEP

Multiple choice questions: ANSWERS

Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

The Big Picture: The current and evolving HIV prevention landscape

HHS Public Access Author manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 01.

ART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK

The Big Picture: The current and evolving HIV prevention landscape

A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)

ART and Prevention: What do we know?

PrEP Dosing Strategies

ARVs for prevention in at-risk populations: Microbicides

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

Update on roll out of PrEP

Second generation HIV surveillance: Better data for decision making

HIV Prevention. Recent Advances and Implications for the Caribbean

PrEP efficacy the evidence

Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE

EVIDENCE-BASED SOCIAL PROTECTION INTERVENTIONS FOR HIV PREVENTION

Novel HIV Prevention Methods for Women

Review of planned trials and key emerging issues for Thailand

HIV PREP THE NEWEST TOOL IN THE BOX

The HIV Prevention Pill: The State of PrEP Science and Implementation

The HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018

Psychosocial Issues in ART and HIV Prevention. Steven A. Safren, PhD

Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location

Profilaxis Antiretroviral para la Prevención de la Infección VIH

CONTINUED LESSONS FROM VOICE

Combination prevention for HIV How to evaluate whether it works? Marie Laga Institute of Tropical Medicine Antwerp, Belgium

HIV In South Africa: Turning the Tide of the Epidemic

Update on Antiretroviral-Based HIV Prevention

Dominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis

Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US

PrEP: Pre Exposure Prophylaxis

Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies

Modelling HIV prevention: strengths and limitations of different modelling approaches

Translating the Science to End New HIV Infections in Kenya

Prevalence and acceptability of male circumcision in South Africa

HIV Prevention among Women

M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010

Strategic use of antiretroviral drugs to prevent HIV transmission

Understanding the Impact of an HIV Intervention Package for Adolescents

Pre-exposure prophylaxis (PrEP) in. in HIV-uninfected individuals with high-risk. behaviour

MTN 034/IPM 045: REACH Rings and PrEP in Young Women

HIV / AIDS. Prevention In Our Lives

TasP - Individual versus Public Health Benefit versus Both.

8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward

International Partnership for Microbicides

11/8/2016. Moving Beyond Truvada: The (Current) Future Pipeline for PrEP. Prevention Modalities

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

E ffective prevention strategies for controlling the HIV pandemic are urgently needed. One potential strategy,

The Evidence Base for Women

HIV: A global perspective on epidemiology, diagnosis and prevention

AFRICAN AND BLACK DIASPORA GLOBAL NETWORK ON HIV AND AIDS ABDGN AIDS 2012 HIGHLIGHTS

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP

What the Science is Saying: making the case for Treat All

PREP EFFICACY AND IMPLEMENTATION WITHIN CLINICAL SETTINGS circle

PrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?

Supplemental Digital Content

Sex Work in Sub-Saharan Africa : Opportunities and Challenges

Modelling the impact of HIV in South Africa s provinces: 2017 update

Can we treat our way out of the HIV epidemic?

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013

Transcription:

Understanding the Impact of an HIV Intervention Package for Adolescents Faikah Bruce Supervisors: Dr. Leigh Johnson (UCT - CIDER) and Prof. Alex Welte (SU - SACEMA) 1

Contents Introduction Literature Review Model Baseline Characteristics Modelling Sexual Behaviour Model Calibration Clinical Trial Simulation Results Conclusion 2

Introduction Aims and Objectives Model the impact of an intervention package on HIV incidence for adolescents in a hypothetical trial The model must be able to determine The HIV incidence without any intervention - compare relevant HIV data The mean relative risk of HIV infection depending which components are included in the intervention package Clinical trial simulation To assist with the design of a RCT Optimal sample size to detect statistically significant effect 3

Literature Review Literature Review Adolescent sexual behaviour: Heterosexual transmission is the most common mode of HIV transmission among adolescents Age of sexual debut, sexual frequency, partnership formation and dissolution, age-mixing, condom use Male Circumcision: practice norms - traditional mc & non-traditional mc Reduced risk associated with mc found in the 3 randomized control trials Study Location Relative Risk (95% C.I.) Auvert et. al (2005) Orange Farm, S.A. 0.40 (0.25-0.70) Grey et. al. (2007) Rakai, Uganda 0.49 (0.30-0.83) Bailey et. al. (2007) Kisumu, Kenya 0.47 (0.28-0.78) 4

Literature Review Vaginal Microbicides: formulations gels; creams; films; rings Literature Review Study Location Protective Effect CAPRISA004 South Africa 39% (95%C.I. 6-60) VOICE (MTN- 003) S.A., Zimbabwe, Uganda No statistically significant results Pre-Exposure Prophylaxis: Study (Group) Location Results iprex : (MSM) FEM-PrEP : (Women) Partners PrEP Study : (HIV1- serodiscordant heterosexual couples) Peru, Ecuador, Brazil, United States, Thailand and South Africa Sub-Saharan Africa Kenya, Uganda Protective effect: 44% (95% C.I. 15-63) No significant result - trial stopped Risk reduction of HIV incidence : TDF arm - 67% (95% C.I. 44 81) TDF-FTC arm - 75% (95%C.I. 5 55 87)

Model Structure Stochastic Model Individual-based simulation Static model Individuals within the model population are stratified by Sex: Male or Female Age: 10-19 years 6

Baseline Characteristics Individual s characteristics Sex: male or female Age: 10-19 years Age of circumcision Age of sexual debut Risk level HIV status Number of partners 7

Baseline Characteristics Age of circumcision Traditional circumcision setting Related the probability of being circumcised to the age of the individual Weibull Distribution - Connolly et al. 2008 Non-traditional circumcision setting No age of circumcision was assigned 8

Baseline Characteristics Age of sexual debut Related the probability of being sexually active to the age of the individual Weibull Distribution LoveLife survey 2003 - Pettifor et al. 2004 National Communication survey 2009 - Johnson et al. 2010 9

Risk level Baseline Characteristics High risk Logit function - 35% in males and 25% in females - Johnson et al. (2009) Negative association between age of sexual debut, s, and the level of risk behaviour Low risk 10

Baseline Characteristics HIV status Log-normal distribution - Williams et al. (2000) Adjusted to determine HIV prevalence in sexually experienced youth Data - Lovelife survey 2003 - Pettifor et al. (2004) 11

Baseline Characteristics Number of partners Multi-state model of sexual behaviour Johnson et al. (2009); Jewkes et al. (2001). Parame ter λi Θi Description Rate of partnership formation Propensity for concurrent partners Hig h Males Females Low High Low 7.3 1.39 14.6 8.76 0.6 4 0 0.54 0 12

Baseline Characteristics Partner s Characteristics Sex Age Average partner age difference of 3 years Assumed male s age is greater than female s age Age difference is assumed to follow a gamma distribution Surveys Lovelife 2003, NCS 2009, HSRC 2008 HIV status Simulated in the same manner as for individual 13

Modelling Sexual Behaviour Time to their next possible event, then which event it could be. Circumcision: age of circumcision Rate of partnership formation: Rate of partnership dissolution: Rate of HIV infection: annu al rate of sex acts HIV transmission rate efficac y of condo m effica cy of MC probability of condom usage 14

Parameter estimates Model Structure Parame ter θi(1) θi(2) n βi ϒ Description Sex Estimate Source Rate of partnership formation Rate of partnership dissolution Annual rate of sexual contact Probability of HIV transmission per act of unprotected sex Probability of condom usage M/F As before Johnson et al. (2009) M/F As before Johnson et al. (2009) M/F 39 Pettifor et al. (2004) Kelly (2000) M F F M 0.0128 0.04 Baeten et al. (2005) Pettifor et al. (2007) M/F 0.6 Shisana et al. (2009) Johnson et al. 15

Model Calibration Model Estimates of HIV Incidence 50 000 individuals over 4 years HRSC 2002-2005 HSRC 2005-2008 16

Model Calibration Model Estimates of HIV Incidence 50 000 individuals over 4 years STI-HIV model ASSA2003 model 17

Clinical Trial Simulation HIV negative individuals aged 15 18 years over a 3 year trial period Intervention options : Males MMC and PrEP Females PrEP, Vaginal Gel or Vaginal Ring Level of Condom Use pth quantile of the beta distribution using the inverse of the cumulative density function Mean: η = 0.60 Variance: κ = 0.15 18

Clinical Trial Simulation Modelling the Acceptability and Uptake of Interventions Positive correlation to level of condom use Modelling of Adherence to Interventions Correlation to level of acceptability Interven tion MMC Mean Acceptability Mean Adherence Efficacy Trad: 0.1 Male Non-Trad: 0.8 Femal e Male Femal e Male Femal e NA NA NA 0.6 NA PrEP 0.7 0.7 0.9 0.9 0.85 0.85 V - Gel NA 0.7 NA 0.6 NA 0.65 19

Clinical Trial Simulation Modelling the HIV Incidence in Trial Modelling sexual behaviour Intervention Arm Control Arm Relative Risk, with 95% C.I. 20

Results Sample size: 2000 1000 Intervention arm 1000 Control arm Simulations: 1000 Interventions MMC PrEP VM Gel VM Ring RCT Full Package 21

Results Sensitivity Analyses Different Packages Package 1: Full Package Package 3: No GEL Package 2: No PrEP Package 4: No RING 22

Results Sensitivity Analyses Different Sample Sizes Sample Size: 500 Sample Size: 2000 Power Detect 80% power, with α=0.05,expected HIV incidence over 3 years of 0.050379, and a mean relative risk of HIV infection of 0.6: sample size required 1550 per arm 23

Results Sensitivity Analyses Negative correlation between level of condom use and acceptability of other interventions Positive Correlation Negative Correlation 24

Conclusion The model assists with the design of a RCT Sensitivity analyses Components to include package to achieve greatest effectiveness Sample size requirements for an optimally powered trial Limitations of the model No variation in the HIV transmission rate True dynamics of relationships are complex only allowed for 2 behavioural states, with a max number of 2 partners in high risk level Future Work Population-level impact Conclusion Impact of drug-related resistance of PrEP and vaginal microbicides 25

Thank you! 26

Baseline Characteristics Age of circumcision Traditional circumcision setting Related the probability of being circumcised to the age of the individual Weibull Distribution - Connolly et al. 2008 (HSRC2002) Non-traditional circumcision setting No age of circumcision was assigned Age of sexual debut Related the probability of being sexually active to the age of the individual Weibull Distribution LoveLife survey 2003 - Pettifor et al. 2004 National Communication survey 2009 - Johnson et al. 2010 27

Baseline Characteristics Risk level High risk Logit function - 35% in males and 25% in females - Johnson et al. (2009) Negative association between age of sexual debut, s, and the level of risk behaviour Low risk HIV status Log-normal distribution - Williams et al. (2000) Adjusted to determine HIV prevalence in sexually experienced youth Data - Lovelife survey 2003 28

Baseline Characteristics Age of sexual debut Related the probability of being sexually active to the age of the individual Weibull Distribution LoveLife survey 2003 - Pettifor et al. 2004 National Communication survey 2009 - Johnson et al. 2010 29

Risk level Baseline Characteristics High risk Logit function - 35% in males and 25% in females - Johnson et al. (2009) Negative association between age of sexual debut, s, and the level of risk behaviour Low risk 30

Baseline Characteristics HIV status Log-normal distribution - Williams et al. (2000) Adjusted to determine HIV prevalence in sexually experienced youth Data - Lovelife survey 2003 - Pettifor et al. (2004) 31

Model Calibration Model Estimates of HIV Incidence 50 000 individuals over 4 years STI-HIV model ASSA2003 model 32